AstraZeneca Made a $1.5 Billion Lung Cancer Bet, but Can Zegfrovy Strengthen its Oncology Growth?

Reported by Yahoo Finance · Published 24 Aug 2026, 3:38 AM MYT (1 hr ago)

Summary

Source & full coverage: this summary is aggregated from Yahoo Finance, the original publisher. Read the complete report for full context, data and quotes.

Read the original report at Yahoo Finance →

Most Recent

FHLC vs. PJP: Which Healthcare ETF Is the Better Buy for Investors? 1 hr ago Vistra Is the Quietest Big Winner of the AI Power Boom. Here's Why. 1 hr ago AstraZeneca Made a $1.5 Billion Lung Cancer Bet, but Can Zegfrovy Strengthen its Oncology Growth? 1 hr ago Major alcohol company shrinks workforce by nearly 2,000 1 hr ago My son does not work, yet pays $500 for Affordable Care Act health insurance. Is that fair? 1 hr ago This Company Has Raised Its Dividend for 72 Straight Years. Almost Nobody Talks About It. 1 hr ago

EconPulse

Markets. Economy. Malaysia & The World.

Independent economic news aggregation for Malaysia, Asia and global markets, updated throughout the day.

Company

About Us Editorial Standards & Corrections Privacy Policy

Work With Us

Submit a Press Release Partnerships & Advertising Contact Us RSS Feed

Contact

editor@econpulse.my

Editorial & newsroom enquiries answered within 1–2 business days.

AstraZeneca Made a $1.5 Billion Lung Cancer Bet, but Can Zegfrovy Strengthen its Oncology Growth?

Summary

More in Markets

FHLC vs. PJP: Which Healthcare ETF Is the Better Buy for Investors?

Vistra Is the Quietest Big Winner of the AI Power Boom. Here's Why.

Major alcohol company shrinks workforce by nearly 2,000

My son does not work, yet pays $500 for Affordable Care Act health insurance. Is that fair?

This Company Has Raised Its Dividend for 72 Straight Years. Almost Nobody Talks About It.

This Chinese Tech Giant Quietly Cut Its Buyback 80% to Fund AI